Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target

Kenjiro Sawada, Anirban Mitra, A. Reza Radjabi, Vinay Bhaskar, Emily O. Kistner, Maria Tretiakova, Sujatha Jagadeeswaran, Anthony Montag, Amy Becker, Hilary A. Kenny, Marcus E. Peter, Vanitha Ramakrishnan, S. Diane Yamada, Ernst Lengyel

Research output: Contribution to journalArticle

244 Citations (Scopus)

Abstract

E-cadherin loss is frequently associated with ovarian cancer metastasis. Given that adhesion to the abdominal peritoneum is the first step in ovarian cancer dissemination, we reasoned that down-regulation of E-cadherin would affect expression of cell matrix adhesion receptors. We show here that inhibition of E-cadherin in ovarian cancer cells causes up-regulation of α5-integrin protein expression and transcription. When E-cadherin was blocked, RMUG-S ovarian cancer cells were able to attach and invade more efficiently. This greater efficiency could, in turn, be inhibited both in vitro and in vivo with an α5β1- integrin-blocking antibody. When E-cadherin is silenced, α5- integrin is up-regulated through activation of an epidermal growth factor receptor/FAK/Erk1-mitogen-activated protein kinase-dependent signaling pathway and not through the canonical E-cadherin/β-catenin signaling pathway. In SKOV-3ip1 ovarian cancer xenografts, which express high levels of A5-integrin, i.p. treatment with an α5β1-integrin antibody significantly reduced tumor burden, ascites, and number of metastasis and increased survival by an average of 12 days when compared with IgG treatment (P < 0.0005). α5-Integrin expression was detected by immunohistochemistry in 107 advanced stage ovarian cancers using a tissue microarray annotated with disease-specific patient follow-up. Ten of 107 tissues (9%) had α5-integrin overexpression, and 39% had some level of α5-integrin expression. The median survival for patients with high α5-integrin levels was 26 months versus 35 months for those with low integrin expression (P < 0.05). Taken together, we have identified α5-integrin upregulation as a molecular mechanism by which E-cadherin loss promotes tumor progression, providing an explanation for how E-cadherin loss increases metastasis. Targeting this integrin could be a promising therapy for a subset of ovarian cancer patients.

Original languageEnglish (US)
Pages (from-to)2329-2339
Number of pages11
JournalCancer Research
Volume68
Issue number7
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Cadherins
Integrins
Ovarian Neoplasms
Neoplasm Metastasis
Therapeutics
Up-Regulation
Cell-Matrix Junctions
Catenins
Blocking Antibodies
Survival
Peritoneum
Mitogen-Activated Protein Kinases
Tumor Burden
Epidermal Growth Factor Receptor
Ascites
Heterografts
Down-Regulation
Immunoglobulin G
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sawada, K., Mitra, A., Radjabi, A. R., Bhaskar, V., Kistner, E. O., Tretiakova, M., ... Lengyel, E. (2008). Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target. Cancer Research, 68(7), 2329-2339. https://doi.org/10.1158/0008-5472.CAN-07-5167

Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target. / Sawada, Kenjiro; Mitra, Anirban; Radjabi, A. Reza; Bhaskar, Vinay; Kistner, Emily O.; Tretiakova, Maria; Jagadeeswaran, Sujatha; Montag, Anthony; Becker, Amy; Kenny, Hilary A.; Peter, Marcus E.; Ramakrishnan, Vanitha; Yamada, S. Diane; Lengyel, Ernst.

In: Cancer Research, Vol. 68, No. 7, 01.04.2008, p. 2329-2339.

Research output: Contribution to journalArticle

Sawada, K, Mitra, A, Radjabi, AR, Bhaskar, V, Kistner, EO, Tretiakova, M, Jagadeeswaran, S, Montag, A, Becker, A, Kenny, HA, Peter, ME, Ramakrishnan, V, Yamada, SD & Lengyel, E 2008, 'Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target', Cancer Research, vol. 68, no. 7, pp. 2329-2339. https://doi.org/10.1158/0008-5472.CAN-07-5167
Sawada, Kenjiro ; Mitra, Anirban ; Radjabi, A. Reza ; Bhaskar, Vinay ; Kistner, Emily O. ; Tretiakova, Maria ; Jagadeeswaran, Sujatha ; Montag, Anthony ; Becker, Amy ; Kenny, Hilary A. ; Peter, Marcus E. ; Ramakrishnan, Vanitha ; Yamada, S. Diane ; Lengyel, Ernst. / Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target. In: Cancer Research. 2008 ; Vol. 68, No. 7. pp. 2329-2339.
@article{e013af76cd204879a9b358c721bbc9ee,
title = "Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target",
abstract = "E-cadherin loss is frequently associated with ovarian cancer metastasis. Given that adhesion to the abdominal peritoneum is the first step in ovarian cancer dissemination, we reasoned that down-regulation of E-cadherin would affect expression of cell matrix adhesion receptors. We show here that inhibition of E-cadherin in ovarian cancer cells causes up-regulation of α5-integrin protein expression and transcription. When E-cadherin was blocked, RMUG-S ovarian cancer cells were able to attach and invade more efficiently. This greater efficiency could, in turn, be inhibited both in vitro and in vivo with an α5β1- integrin-blocking antibody. When E-cadherin is silenced, α5- integrin is up-regulated through activation of an epidermal growth factor receptor/FAK/Erk1-mitogen-activated protein kinase-dependent signaling pathway and not through the canonical E-cadherin/β-catenin signaling pathway. In SKOV-3ip1 ovarian cancer xenografts, which express high levels of A5-integrin, i.p. treatment with an α5β1-integrin antibody significantly reduced tumor burden, ascites, and number of metastasis and increased survival by an average of 12 days when compared with IgG treatment (P < 0.0005). α5-Integrin expression was detected by immunohistochemistry in 107 advanced stage ovarian cancers using a tissue microarray annotated with disease-specific patient follow-up. Ten of 107 tissues (9{\%}) had α5-integrin overexpression, and 39{\%} had some level of α5-integrin expression. The median survival for patients with high α5-integrin levels was 26 months versus 35 months for those with low integrin expression (P < 0.05). Taken together, we have identified α5-integrin upregulation as a molecular mechanism by which E-cadherin loss promotes tumor progression, providing an explanation for how E-cadherin loss increases metastasis. Targeting this integrin could be a promising therapy for a subset of ovarian cancer patients.",
author = "Kenjiro Sawada and Anirban Mitra and Radjabi, {A. Reza} and Vinay Bhaskar and Kistner, {Emily O.} and Maria Tretiakova and Sujatha Jagadeeswaran and Anthony Montag and Amy Becker and Kenny, {Hilary A.} and Peter, {Marcus E.} and Vanitha Ramakrishnan and Yamada, {S. Diane} and Ernst Lengyel",
year = "2008",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-07-5167",
language = "English (US)",
volume = "68",
pages = "2329--2339",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target

AU - Sawada, Kenjiro

AU - Mitra, Anirban

AU - Radjabi, A. Reza

AU - Bhaskar, Vinay

AU - Kistner, Emily O.

AU - Tretiakova, Maria

AU - Jagadeeswaran, Sujatha

AU - Montag, Anthony

AU - Becker, Amy

AU - Kenny, Hilary A.

AU - Peter, Marcus E.

AU - Ramakrishnan, Vanitha

AU - Yamada, S. Diane

AU - Lengyel, Ernst

PY - 2008/4/1

Y1 - 2008/4/1

N2 - E-cadherin loss is frequently associated with ovarian cancer metastasis. Given that adhesion to the abdominal peritoneum is the first step in ovarian cancer dissemination, we reasoned that down-regulation of E-cadherin would affect expression of cell matrix adhesion receptors. We show here that inhibition of E-cadherin in ovarian cancer cells causes up-regulation of α5-integrin protein expression and transcription. When E-cadherin was blocked, RMUG-S ovarian cancer cells were able to attach and invade more efficiently. This greater efficiency could, in turn, be inhibited both in vitro and in vivo with an α5β1- integrin-blocking antibody. When E-cadherin is silenced, α5- integrin is up-regulated through activation of an epidermal growth factor receptor/FAK/Erk1-mitogen-activated protein kinase-dependent signaling pathway and not through the canonical E-cadherin/β-catenin signaling pathway. In SKOV-3ip1 ovarian cancer xenografts, which express high levels of A5-integrin, i.p. treatment with an α5β1-integrin antibody significantly reduced tumor burden, ascites, and number of metastasis and increased survival by an average of 12 days when compared with IgG treatment (P < 0.0005). α5-Integrin expression was detected by immunohistochemistry in 107 advanced stage ovarian cancers using a tissue microarray annotated with disease-specific patient follow-up. Ten of 107 tissues (9%) had α5-integrin overexpression, and 39% had some level of α5-integrin expression. The median survival for patients with high α5-integrin levels was 26 months versus 35 months for those with low integrin expression (P < 0.05). Taken together, we have identified α5-integrin upregulation as a molecular mechanism by which E-cadherin loss promotes tumor progression, providing an explanation for how E-cadherin loss increases metastasis. Targeting this integrin could be a promising therapy for a subset of ovarian cancer patients.

AB - E-cadherin loss is frequently associated with ovarian cancer metastasis. Given that adhesion to the abdominal peritoneum is the first step in ovarian cancer dissemination, we reasoned that down-regulation of E-cadherin would affect expression of cell matrix adhesion receptors. We show here that inhibition of E-cadherin in ovarian cancer cells causes up-regulation of α5-integrin protein expression and transcription. When E-cadherin was blocked, RMUG-S ovarian cancer cells were able to attach and invade more efficiently. This greater efficiency could, in turn, be inhibited both in vitro and in vivo with an α5β1- integrin-blocking antibody. When E-cadherin is silenced, α5- integrin is up-regulated through activation of an epidermal growth factor receptor/FAK/Erk1-mitogen-activated protein kinase-dependent signaling pathway and not through the canonical E-cadherin/β-catenin signaling pathway. In SKOV-3ip1 ovarian cancer xenografts, which express high levels of A5-integrin, i.p. treatment with an α5β1-integrin antibody significantly reduced tumor burden, ascites, and number of metastasis and increased survival by an average of 12 days when compared with IgG treatment (P < 0.0005). α5-Integrin expression was detected by immunohistochemistry in 107 advanced stage ovarian cancers using a tissue microarray annotated with disease-specific patient follow-up. Ten of 107 tissues (9%) had α5-integrin overexpression, and 39% had some level of α5-integrin expression. The median survival for patients with high α5-integrin levels was 26 months versus 35 months for those with low integrin expression (P < 0.05). Taken together, we have identified α5-integrin upregulation as a molecular mechanism by which E-cadherin loss promotes tumor progression, providing an explanation for how E-cadherin loss increases metastasis. Targeting this integrin could be a promising therapy for a subset of ovarian cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=42049107076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049107076&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-5167

DO - 10.1158/0008-5472.CAN-07-5167

M3 - Article

C2 - 18381440

AN - SCOPUS:42049107076

VL - 68

SP - 2329

EP - 2339

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -